Clinical and Pathological Characteristics and Treatment Implications of <i>BRCA1</i> - and <i>BRCA2</i> -Mutated Breast Cancer in Japanese Patients: A Single-Institution Retrospective Study
This single-institution study highlights clinically meaningful differences between <i>BRCA1</i>- and <i>BRCA2</i>-associated BC in Japanese patients. <i>BRCA2</i> cancers tended to present with more advanced features, while <i>BRCA1</i> cancers were more often detected at earlier stage. These findings underscore the value of <i>BRCA</i> testing not only for PARP inhibitor eligibility but also for subtype-specific risk assessment and individualized preventive strategies.
Authors
- Yuko Takano (ORCID: https://orcid.org/0000-0002-3753-7683)
- Takahiro Ichikawa (ORCID: https://orcid.org/0000-0002-2545-5410)
- Yoshiko Akita (ORCID: https://orcid.org/0009-0001-7333-5448)
- Madoka Iwase (ORCID: https://orcid.org/0000-0002-4423-4023)
- Toyone Kikumori
- Norikazu Masuda (ORCID: https://orcid.org/0000-0002-7302-0278)
- Dai Takeuchi
Institutions
- Kyoto University (JP)
- Nagoya University Hospital (JP)
- Nagoya University (JP)
Publication Details
- Journal
- Breast Cancer Basic and Clinical Research
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1177/11782234251399355
- Primary Topic
- BRCA gene mutations in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00